Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2017 Nov;96(47):e8922.
doi: 10.1097/MD.0000000000008922.

A recurrence-free survivor with chemotherapy-refractory small cell lung cancer after pneumonectomy: A case report and review of the literature

Yong Pan  1 , Feng-Wei Kong, Heng Wang, Xiang Wang, Hui Zhang, Wen-Bin Wu, Miao Zhang
Affiliations
Review

A recurrence-free survivor with chemotherapy-refractory small cell lung cancer after pneumonectomy: A case report and review of the literature

Yong Pan et al. Medicine (Baltimore). 2017 Nov.

Abstract

Rationale: The optimal therapeutic regimen for chemotherapy-refractory and node-positive small-cell lung cancer (SCLC) is criticizable for the lack of evidence.

Patient concerns: A patient with locally advanced SCLC was insensitive to the first-line chemotherapy of etoposide, irinotecan, and cisplatin.

Diagnoses: The patient was diagnosed as SCLC with mediastinal lymph node metastasis by pathological staining.

Interventions: Salvage pneumonectomy and systematic lymph node dissection combined with oral apatinib and mediastinal radiotherapy were performed for him.

Outcomes: The patient survived for more than 2 years without recurrence after the operation and adjuvant therapy.

Lessons: For patients with chemotherapy-resistant but resectable SCLC, a timely resection combined with postoperative radiotherapy and apatinib might be effective.

PubMed Disclaimer

Conflict of interest statement

The authors have no funding and conflicts of interest to disclose.

Figures

Figure 1
Figure 1
(A) CT scan on June 5, 2015 showed progressed central-type lung cancer after the first cycle chemotherapy using etoposide. (B) The tumor enlarged after the second cycle of etoposide. (C) The tumor progressed after the third cycle of chemotherapy using irinotecan. (D) Pathological staining of a tumor section indicated SCLC, by H-E staining (×200), on August 7, 2015. CT = computed tomography, SCLC = small-cell lung cancer.
Figure 2
Figure 2
The schematic illustration of therapeutic regimen of the patient. EP = etoposide and cisplatin, GP = gemcitabine and cisplatin, IP = irinotecan and cisplatin, RT = radiotherapy.
See this image and copyright information in PMC

References

    1. Byers LA, Rudin CM. Small cell lung cancer: where do we go from here? Cancer 2015;121:664–72. - PMC - PubMed
    1. Rudin CM, Ismaila N, Hann CL, et al. Treatment of small-cell lung cancer: American Society of Clinical Oncology Endorsement of the American College of Chest Physicians Guideline. J Clin Oncol 2015;33:4106–11. - PubMed
    1. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: small cell lung cancer, Version 3.2017. Available at: https://www.nccn.org/professionals/physician_gls/pdf/sclc.pdf. Accessed ..., 2017.
    1. Yang CJ, Chan DY, Shah SA, et al. Long-term survival after surgery compared with concurrent chemoradiation for node-negative small cell lung cancer. Ann Surg 2017;doi: 10.1097/SLA.0000000000002287. - PubMed
    1. Ding L, Li QJ, You KY, et al. The use of apatinib in treating nonsmall-cell lung cancer: case report and review of literature. Medicine (Baltimore) 2016;95:e3598. - PMC - PubMed